Verona Pharma PLC VRNA
We take great care to ensure that the data presented and summarized in this overview for Verona Pharma plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VRNA
View all-
Perceptive Advisors LLC New York, NY6.32MShares$223 Million4.75% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$198 Million12.27% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.01MShares$177 Million2.01% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx4.22MShares$149 Million2.52% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$126 Million14.95% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$120 Million5.24% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.18MShares$112 Million3.37% of portfolio
-
Abingworth LLP London, X02.46MShares$86.9 Million21.3% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.43MShares$85.8 Million1.23% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA2.17MShares$76.7 Million0.14% of portfolio
Latest Institutional Activity in VRNA
Top Purchases
Top Sells
About VRNA
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Insider Transactions at VRNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 11
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,400
-0.02%
|
$12,000
$5.0 P/Share
|
|
Nov 11
2024
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
2,400
-0.02%
|
$12,000
$5.0 P/Share
|
|
Nov 06
2024
|
Christina Ackermann Director |
BUY
Open market or private purchase
|
Direct |
41,880
+50.0%
|
$167,520
$4.74 P/Share
|
|
Nov 06
2024
|
David R Ebsworth Director |
BUY
Open market or private purchase
|
Direct |
39,360
+4.1%
|
$157,440
$4.8 P/Share
|
|
Nov 04
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
80,784
-0.56%
|
$323,136
$4.39 P/Share
|
|
Nov 04
2024
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
94,144
-0.62%
|
$376,576
$4.39 P/Share
|
|
Nov 01
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
48,888
-0.34%
|
$195,552
$4.38 P/Share
|
|
Nov 01
2024
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
46,888
-0.31%
|
$187,552
$4.38 P/Share
|
|
Nov 01
2024
|
David Zaccardelli President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
245,952
-1.58%
|
$983,808
$4.24 P/Share
|
|
Nov 01
2024
|
David Zaccardelli President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+1.27%
|
-
|
|
Nov 01
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
245,952
-1.68%
|
$983,808
$4.24 P/Share
|
|
Nov 01
2024
|
Mark W Hahn Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+1.35%
|
-
|
|
Nov 01
2024
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
65,936
-2.21%
|
$263,744
$4.24 P/Share
|
|
Nov 01
2024
|
Kathleen A. Rickard Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+1.65%
|
-
|
|
Oct 30
2024
|
David Zaccardelli President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
800,000
+4.94%
|
-
|
|
Oct 30
2024
|
Mark W Hahn Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
800,000
+5.24%
|
-
|
|
Oct 30
2024
|
Kathleen A. Rickard Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+9.3%
|
-
|
|
Oct 30
2024
|
Andrew Fisher General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+50.0%
|
-
|
|
Oct 25
2024
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
4,800
-0.03%
|
$19,200
$4.38 P/Share
|
|
Oct 25
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,200
-0.02%
|
$12,800
$4.38 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 151K shares |
|---|---|
| Grant, award, or other acquisition | 4.45M shares |
| Bona fide gift | 117K shares |
| Payment of exercise price or tax liability | 2.95M shares |
|---|---|
| Open market or private sale | 3.68M shares |
| Bona fide gift | 117K shares |